{"id":"NCT01815424","sponsor":"Pfizer","briefTitle":"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis","officialTitle":"A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN ASIAN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12","primaryCompletion":"2015-07","completion":"2015-07","firstPosted":"2013-03-21","resultsPosted":"2019-03-05","lastUpdate":"2019-04-16"},"enrollment":266,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"CP-690,550","otherNames":[]}],"arms":[{"label":"Placebo BID","type":"PLACEBO_COMPARATOR"},{"label":"5mg BID CP-690,550","type":"EXPERIMENTAL"},{"label":"10mg BID CP-690,550","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.","primaryOutcome":{"measure":"Percentage of Participants With Physician's Global Assessment (PGA) Score of \"Clear\" or \"Almost Clear\" at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Tofacitinib 10 mg","deltaMin":75.56,"sd":null},{"arm":"Tofacitinib 5 mg","deltaMin":52.27,"sd":null},{"arm":"Placebo","deltaMin":19.32,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":24,"countries":["China","South Korea","Taiwan"]},"refs":{"pmids":["28558978"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921174&StudyName=A%20Study%20Evaluating%20The%20Efficacy%20And%20Safety%20oO%20CP-690%2C550%20In%20Asian%20Subjects%20With%20Moderate%20To%20Severe%20Plaque%20Psoriasis"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":90},"commonTop":["Hyperlipidaemia","Upper respiratory tract infection","Nasopharyngitis","Blood cholesterol increased","Blood triglycerides increased"]}}